Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04016805
Title Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib or Venetoclax
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.

chronic lymphocytic leukemia


Ublituximab + Umbralisib + Venetoclax

Ibrutinib + Ublituximab + Umbralisib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.